Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial.

Journal of the American College of Cardiology·2026
Same author

Bird occurrence and trophic interactions vary across gradients of tree diversity and microclimate in a planted forest.

Ecological applications : a publication of the Ecological Society of America·2026
Same author

Leaf litter and fine roots have distinct effects on particulate and mineral-associated soil organic matter in a tree common garden.

The New phytologist·2026
Same author

Diversity in Resource Use Strategies Promotes Productivity in Young Planted Tree Species Mixtures.

Global change biology·2025
Same author

The tree growth-herbivory relationship depends on functional traits across forest biodiversity experiments.

Nature ecology & evolution·2025
Same author

Canopy complexity drives positive effects of tree diversity on productivity in two tree diversity experiments.

Ecology·2025

Related Experiment Videos

Rosiglitazone causes endothelial dysfunction in humans.

Kumar Perampaladas1, Tommaso Gori, John D Parker

  • 1Division of Cardiology, Department of Medicine, University of Health Network and Mount Sinai Hospitals, University of Toronto, Toronto, Ontario, Canada.

Journal of Cardiovascular Pharmacology and Therapeutics
|November 5, 2011
PubMed
Summary
This summary is machine-generated.

Rosiglitazone unexpectedly impaired endothelial function in healthy individuals, contrary to expectations. This finding suggests potential risks for drug development and patient monitoring.

Related Experiment Videos

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Endothelial Function Studies

Background:

  • Endothelial dysfunction is a key factor in cardiovascular disease.
  • The thiazolidinedione class, including rosiglitazone, is used to treat type 2 diabetes.
  • Glyceryl trinitrate (GTN) is a vasodilator used to treat angina.

Purpose of the Study:

  • To investigate the effect of rosiglitazone on endothelial function in healthy volunteers.
  • To examine the interaction between rosiglitazone and GTN-induced endothelial dysfunction.

Main Methods:

  • A double-blind, randomized, placebo-controlled study involving 44 participants.
  • Participants received placebo, rosiglitazone, transdermal GTN, or a combination.
  • Forearm blood flow was measured using acetylcholine infusion; glucose metabolism and insulin sensitivity were assessed.

Main Results:

  • Rosiglitazone treatment led to blunted endothelium-dependent responses to acetylcholine.
  • GTN administration induced similar endothelial dysfunction.
  • Vitamin C partially improved endothelial function in GTN-treated individuals but not in those receiving both rosiglitazone and GTN.

Conclusions:

  • Rosiglitazone therapy unexpectedly caused endothelial dysfunction in healthy volunteers.
  • These results highlight potential implications for drug development and post-market surveillance of rosiglitazone.
  • The findings challenge the assumption of a neutral effect of rosiglitazone on endothelial function.